Benzimidazole analogs inhibit respiratory syncytial virus G protein function

Carrie W. Evans, Colm Atkins, Ashish Pathak, Brian E. Gilbert, James W. Noah

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Abstract Human respiratory syncytial virus (hRSV) is a highly contagious Paramyxovirus that infects most children by age two, generating an estimated 75,000-125,000 hospitalizations in the U.S. annually. hRSV is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age, with significant mortality among high-risk groups. A regulatory agency-approved vaccine is not available, and existing prophylaxis and therapies are limited to use in high-risk pediatric patients; thus additional therapies are sorely needed. Here, we identify a series of benzimidazole analogs that inhibit hRSV infection in vitro with high potency, using a previously-reported high-throughput screening assay. The lead compound, SRI 29365 (1-[6-(2-furyl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl]methyl-1H-benzimidazole), has an EC50 of 66 μM and a selectivity >50. We identified additional compounds with varying potencies by testing commercially-available chemical analogs. Time-of-addition experiments indicated that SRI 29365 effectively inhibits viral replication only if present during the early stages of viral infection. We isolated a virus with resistance to SRI 29365 and identified mutations in the transmembrane domain of the viral G protein genomic sequence that suggested that the compound inhibits G-protein mediated attachment of hRSV to cells. Additional experiments with multiple cell types indicated that SRI 29365 antiviral activity correlates with the binding of cell surface heparin by full-length G protein. Lastly, SRI 29365 did not reduce hRSV titers or morbidity/mortality in efficacy studies using a cotton rat model. Although SRI 29365 and analogs inhibit hRSV replication in vitro, this work suggests that the G-protein may not be a valid drug target in vivo.

Original languageEnglish (US)
Article number3656
Pages (from-to)31-38
Number of pages8
JournalAntiviral research
Volume121
DOIs
StatePublished - Jul 3 2015

    Fingerprint

Keywords

  • Antiviral
  • G protein
  • Heparin
  • SAR
  • hRSV

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

Evans, C. W., Atkins, C., Pathak, A., Gilbert, B. E., & Noah, J. W. (2015). Benzimidazole analogs inhibit respiratory syncytial virus G protein function. Antiviral research, 121, 31-38. [3656]. https://doi.org/10.1016/j.antiviral.2015.06.016